Axogen Inc. Common Stock (AXGN)
Stock · NASDAQ · Health Care
$34.62as of 10/16/2026
Price chart
Active signals
AXGN Signal Track Record
How signals performed across all stocks →What AXGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +1.3% | 55% | October 2, 2026 |
| Bollinger Band Breakout | 26 | +5.2% | 54% | August 3, 2026 |
| Bollinger Band Breakdown | 18 | +0.2% | 50% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +5.3% | 60% | August 13, 2025 |
| Any 20-session window (baseline) | +2.2% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AXGN
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a ten…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 622
- Website
- www.axogeninc.com/
Fundamentals
- 1-day range
- $34.66$35.65
- Market cap
- $2.38B
- P/E (trailing)
- —
- P/E (forward)
- 48.62
- EPS (trailing)
- $-0.68
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 1.22M
- Ex-dividend date
- January 27, 2010
- Dividend pay date
- February 12, 2010
How Axogen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Axogen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AXGNAxogen Inc. Common Stock$34.62▼ 2.83%Market cap $2.38BP/E —$15.27$52.91
- TMDXTransMedics Group Inc. Common Stock$70.78▼ 7.50%Market cap $2.78BP/E 17.33$60.11$156
- CNMDCONMED Corporation Common Stock$46.72▼ 0.89%Market cap $1.49BP/E 25.13$31.44$53.66
- INMDInMode Ltd. Ordinary Shares$14.16▼ 1.12%Market cap $957.98MP/E 10.66$12.72$16.67
- CBLLCeriBell Inc. Common Stock$25.04▼ 9.41%Market cap $692.45MP/E —$10.85$26.63
- LIVNLivaNova PLC Ordinary Shares$77.58▼ 1.17%Market cap $4.16BP/E 22.41$48.82$85.76
- CVCapsoVision Inc. Common Stock$6.53▲ 1.24%Market cap $344.75MP/E —$4.46$15.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AXGN Axogen Inc. Common Stock | $2.38B | — | $34.62 | ▼ 2.83% | $15.27$52.91 |
| TMDX TransMedics Group Inc. Common Stock | $2.78B | 17.33 | $70.78 | ▼ 7.50% | $60.11$156 |
| CNMD CONMED Corporation Common Stock | $1.49B | 25.13 | $46.72 | ▼ 0.89% | $31.44$53.66 |
| INMD InMode Ltd. Ordinary Shares | $957.98M | 10.66 | $14.16 | ▼ 1.12% | $12.72$16.67 |
| CBLL CeriBell Inc. Common Stock | $692.45M | — | $25.04 | ▼ 9.41% | $10.85$26.63 |
| LIVN LivaNova PLC Ordinary Shares | $4.16B | 22.41 | $77.58 | ▼ 1.17% | $48.82$85.76 |
| CV CapsoVision Inc. Common Stock | $344.75M | — | $6.53 | ▲ 1.24% | $4.46$15.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- B of A Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $52benzinga · 10/12/2026
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekYahoo · 10/3/2026
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve RepairYahoo · 10/1/2026
- Truist Securities Maintains Buy on Axogen, Lowers Price Target to $53Benzinga · 10/1/2026
- 3 Emerging Biotech Stocks With Significant Upside PotentialYahoo · 9/30/2026
- AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · 9/25/2026
- Raymond James Maintains Outperform on Axogen, Raises Price Target to $53Benzinga · 9/25/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 9/24/2026
Insider Activity
Insider Actions →- TYNDALL JOSEPH A. · September 2, 2026 · Sale3.5K @ $49.7
- Amy McBride Wendell · August 11, 2026 · Option Exercise13.4K @ $14.85
- Amy McBride Wendell · August 11, 2026 · Sale13.4K @ $48.42
- Began Marc A · August 10, 2026 · Option Exercise67.5K @ $8.16
- Began Marc A · August 10, 2026 · Sale67.5K @ $47.35
- Weiler Kathy Johnson · August 7, 2026 · Sale14.2K @ $45.3
- Burke William P. Mr. · June 24, 2026 · Grant4.4K
- Weiler Kathy Johnson · June 24, 2026 · Grant4.4K
- TYNDALL JOSEPH A. · June 24, 2026 · Grant4.4K
- Levine Alan M · June 24, 2026 · Grant4.4K
- John Johnson · June 24, 2026 · Grant4.4K
- Amy McBride Wendell · June 24, 2026 · Grant4.4K
- Paul Thomas · June 24, 2026 · Grant5.6K
- Weiler Kathy Johnson · June 19, 2026 · Option Exercise14.2K
- TYNDALL JOSEPH A. · June 19, 2026 · Option Exercise14.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 48.79M
- Total value held
- $1.58B
- Institutional holders
- 214
- Unknown4.00M
- Unknown3.87M
- Unknown3.12M
- Unknown2.29M
- Unknown1.92M
- Unknown1.86M
- Unknown1.50M
- Unknown1.38M
- Unknown1.31M
- Unknown1.22M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Axogen Receives New Analyst Coverage and Valuation Upside
Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.
Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.